UMB Bank n.a. Buys 168 Shares of Bio-Techne Co. (NASDAQ:TECH)

UMB Bank n.a. grew its stake in shares of Bio-Techne Co. (NASDAQ:TECH) by 46.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 530 shares of the biotechnology company’s stock after acquiring an additional 168 shares during the quarter. UMB Bank n.a.’s holdings in Bio-Techne were worth $38,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Brooklyn Investment Group bought a new stake in shares of Bio-Techne in the third quarter worth approximately $39,000. Quest Partners LLC purchased a new stake in Bio-Techne during the 3rd quarter valued at $43,000. Mather Group LLC. lifted its holdings in shares of Bio-Techne by 51.5% during the 3rd quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 208 shares during the period. Sentry Investment Management LLC bought a new stake in shares of Bio-Techne in the third quarter worth $59,000. Finally, Huntington National Bank increased its position in Bio-Techne by 38.5% during the third quarter. Huntington National Bank now owns 756 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Bio-Techne Trading Up 0.2 %

Shares of TECH opened at $77.05 on Friday. Bio-Techne Co. has a twelve month low of $61.16 and a twelve month high of $85.57. The company has a current ratio of 4.56, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14. The company’s fifty day simple moving average is $74.22 and its 200-day simple moving average is $74.53. The company has a market cap of $12.24 billion, a P/E ratio of 81.97, a P/E/G ratio of 5.80 and a beta of 1.27.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04. The firm had revenue of $289.46 million for the quarter, compared to analysts’ expectations of $280.22 million. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.35 earnings per share. As a group, analysts expect that Bio-Techne Co. will post 1.68 EPS for the current year.

Bio-Techne Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 22nd. Shareholders of record on Monday, November 11th were issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend was Friday, November 8th. Bio-Techne’s payout ratio is 34.04%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Robert W. Baird boosted their price objective on shares of Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Scotiabank raised their target price on Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a report on Thursday, October 31st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.00.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.